China Pharma Holdings (CPHI) Short term Debt (2010 - 2026)

China Pharma Holdings' Short term Debt history runs 17 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• Quarterly Short term Debt rose 55.94% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 55.94% YoY) and the FY2025 annual result came in at $1.4 million, up 25.34% from the prior year.
• Short term Debt was $1.5 million for Q1 2026 at China Pharma Holdings, up from $1.4 million in the prior quarter.
• Across five years, Short term Debt topped out at $4.3 million in Q1 2022 and bottomed at $940173.0 in Q1 2025.
• A 5-year average of $1.9 million and a median of $1.4 million in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2022 — Short term Debt soared 282.05% — and 2023, when it slumped 66.73%.
• China Pharma Holdings' Short term Debt stood at $2.4 million in 2022, then slumped by 53.55% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024, then gained by 25.34% to $1.4 million in 2025, then advanced by 2.16% to $1.5 million in 2026.
• Business Quant data shows CPHI's Short term Debt at $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $2.0 million in Q3 2025.